Modulation of PKC Response and Insulin Secretion by the Beta Subunit of Calcium C
钙 C 的 β 亚基对 PKC 反应和胰岛素分泌的调节
基本信息
- 批准号:8268212
- 负责人:
- 金额:$ 10.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-10 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgonistAmericanAntidiabetic DrugsBindingBlood GlucoseCalciumCalcium ChannelCellsCenters for Disease Control and Prevention (U.S.)ChemosensitizationDevelopmentDiabetes MellitusDown-RegulationFamilyGenerationsGlucoseGoalsGuanylate kinaseHypoglycemiaIn VitroInsulinInvestigationIon ChannelIslets of LangerhansIsoenzymesKnock-outKnowledgeLaboratoriesLeadLifeLinkMaintenanceMasksMembraneMusNon-Insulin-Dependent Diabetes MellitusOralPancreasPhosphorylationPhosphorylation SitePlayPrincipal InvestigatorProtein Kinase CProteinsRegulationRoleSignal PathwaySiteSmall Interfering RNASystemXenopus oocytebaseblood glucose regulationdiabeticdiabetic patientglucose tolerancein vivoinsightinsulin secretagoguesinsulin secretionmemberprogramsresponsescaffoldtraffickingvoltage
项目摘要
DESCRIPTION (provided by applicant): Insulin plays the major role in the maintenance of glucose homeostasis based on the concentration of blood glucose. However, the release of insulin independent of blood glucose concentration will lead to hypoglycemia which often takes place with the administration of currently available antidiabetic drugs. Hence, the ideal treatment
for diabetes is to increase insulin concentration based on blood glucose level. The identification of such a phenomenon is the long-term goal of our laboratory. Glucose-dependent insulin secretion is increased in voltage-gated Ca2+-channel (Cav) ¿3 subunit knockout (¿3-/-) mice. The Cav¿-knockout-induced increase of insulin secretion is called negative modulation since Cav¿ subunits may be inhibiting insulin secretion when they are available. Cav¿ subunits, in addition to being an auxiliary subunit of Cav channels, act independently in scaffolding multiple signaling pathways around the channel since they belong to the membrane activated guanylate kinase (MAGUK) family. Hence it is possible that Cav¿ subunits negatively modulated insulin secretion by interacting with the intermediaries involved in insulin secretion. The identification f the targets of Cav¿ subunits and the understanding of the mechanisms leading to their negative modulation of insulin secretion is the aim of this proposal. Cav¿ subunits are functionally linked
to Cav channels and protein kinase C (PKC) family of isozymes, the two secretagogues of insulin secretion. These subunits are required for the trafficking of Cav ¿1 subunits and their assembly as Cav channels in the membrane and their modulation by PKC. Hence, it is likely that either Cav ¿1 subunits and PKC isozymes or both are the targets of Cav¿ subunits in their negative modulation of insulin secretion. We will study the negative modulation by inhibiting the Cav¿ subunits and examining the insulin release, the activity of Cav channels and PKC isozymes. In this regard, we will use small interfering RNA (siRNA) to silence the selected Cav subunits. The Specific Aim I will identify the Cav¿ subunits (¿1- ¿4) that modulated insulin secretion and the PKC isoymes (cPKCs, nPKCs and aPKCs) that the implicated Cav¿ activated. The Specific Aim II will identify the Cav channels (Cav 1.2, 1.3, 2.1 and 2.3) with which the implicated Cav¿ and PKC isozymes interact. These two Specific Aims will use in vivo studies in mice and in vitro studies employing mouse cultured pancreatic -¿ cells. The Specific Aim III will study the mechanism of interaction between the implicated Cav ¿1 and ¿ subunits and the PKC isozymes employing Xenopus oocytes expression system. To be specific, this Aim will identify the Ser/Thr PKC phosphorylation sites of Cav ¿1 subunits that are targeted by the Cav¿ and PKC isozymes and study the mechanism of interaction between these three proteins.
PUBLIC HEALTH RELEVANCE: This proposal puts forward a new mechanism of insulin secretion that is controlled by calcium channels and analyses the contribution of various modulators. The understanding of this mechanism will provide a better strategy for the control and treatment of diabetes.
描述(申请人提供):根据血糖浓度,胰岛素在维持血糖稳态中起主要作用。然而,胰岛素的释放与血糖浓度无关,会导致低血糖,这通常发生在使用现有的抗糖尿病药物时。因此,理想的治疗方法
对于糖尿病来说,就是要根据血糖水平增加胰岛素浓度。识别这种现象是我们实验室的长期目标。电压门控钙通道(Cav)3亚单位基因敲除(?3-/-)小鼠的葡萄糖依赖性胰岛素分泌增加。Cav基因敲除诱导的胰岛素分泌增加被称为负调节,因为Cav亚单位可能会抑制胰岛素的分泌。Cav?亚基除了是Cav通道的一个辅助亚单位外,由于属于膜激活鸟苷酸激酶(Maguk)家族,因此在通道周围的多条信号通路中起着独立的作用。因此,Cav亚基可能通过与参与胰岛素分泌的中间体相互作用而负向调节胰岛素的分泌。识别Cav亚基的靶标并了解其负性调节胰岛素分泌的机制是本方案的目的。CaV?亚基在功能上是相连的
Cav通道和蛋白激酶C(PKC)家族的同工酶是胰岛素分泌的两种促分泌剂。这些亚基对于Cav?1亚基的运输和它们作为Cav通道在膜上的组装以及它们被PKC的调节是必需的。因此,Cav?1亚基和PKC同工酶或两者都是Cav?亚基负性调节胰岛素分泌的靶标。我们将通过抑制Cav亚基、检测胰岛素释放、Cav通道活性和PKC同工酶来研究负调控。在这方面,我们将使用小干扰RNA(SiRNA)来沉默选定的Cav亚基。具体目的I将确定调节胰岛素分泌的Cav亚基(1-4)和被牵连的Cav激活的PKC同工酶(cPKCs、nPKCs和aPKCs)。特定的目标II将确定与所涉及的Cav?和PKC同工酶相互作用的Cav通道(Cav 1.2、1.3、2.1和2.3)。这两个特定的目标将使用在小鼠体内的研究和使用小鼠培养的胰腺细胞的体外研究。具体目标III将利用非洲爪哇卵母细胞表达系统研究涉及的Cav?1和?亚基之间的相互作用机制以及PKC同工酶。具体地说,这一目标将确定Cav和PKC同工酶靶向的Cav?1亚基的Ser/Thr PKC磷酸化位点,并研究这三种蛋白之间的相互作用机制。
与公众健康相关:这项建议提出了一种由钙通道控制的新的胰岛素分泌机制,并分析了各种调节剂的贡献。对这一机制的认识将为糖尿病的控制和治疗提供更好的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GANESAN Lenin KAMATCHI其他文献
GANESAN Lenin KAMATCHI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GANESAN Lenin KAMATCHI', 18)}}的其他基金
Modulation of PKC Response and Insulin Secretion by the Beta Subunit of Calcium C
钙 C 的 β 亚基对 PKC 反应和胰岛素分泌的调节
- 批准号:
8878292 - 财政年份:2012
- 资助金额:
$ 10.28万 - 项目类别:
Modulation of PKC Response and Insulin Secretion by the Beta Subunit of Calcium C
钙 C 的 β 亚基对 PKC 反应和胰岛素分泌的调节
- 批准号:
8523914 - 财政年份:2012
- 资助金额:
$ 10.28万 - 项目类别:
Modulation of PKC Response and Insulin Secretion by the Beta Subunit of Calcium C
钙 C 的 β 亚基对 PKC 反应和胰岛素分泌的调节
- 批准号:
8656363 - 财政年份:2012
- 资助金额:
$ 10.28万 - 项目类别:
PKC modulation of calcium current and anesthetic action
PKC 调节钙电流和麻醉作用
- 批准号:
7266199 - 财政年份:2003
- 资助金额:
$ 10.28万 - 项目类别:
PKC modulation of calcium current and anesthetic action
PKC 调节钙电流和麻醉作用
- 批准号:
6765977 - 财政年份:2003
- 资助金额:
$ 10.28万 - 项目类别:
PKC modulation of calcium current and anesthetic action
PKC 调节钙电流和麻醉作用
- 批准号:
7101698 - 财政年份:2003
- 资助金额:
$ 10.28万 - 项目类别:
PKC modulation of calcium current and anesthetic action
PKC 调节钙电流和麻醉作用
- 批准号:
6679044 - 财政年份:2003
- 资助金额:
$ 10.28万 - 项目类别:
PKC modulation of calcium current and anesthetic action
PKC 调节钙电流和麻醉作用
- 批准号:
6927927 - 财政年份:2003
- 资助金额:
$ 10.28万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 10.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 10.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 10.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)